Personalis, Inc.
A cancer genomics company that reads the full DNA of a patient's tumor to help doctors spot cancer returning earlier than scans can. Its flagship test, NeXT Personal, is a liquid biopsy that hunts for tiny traces of tumor DNA in a blood sample. Founded in 2011 by Stanford University researchers, the company's name comes from "personalized" medicine — tailoring cancer care to each patient's unique genetic makeup.
Bought 3.82M
Granted 287.5K · Sold 276.5K
Granted 274.3K · Sold 268.8K
Granted 46.9K · Sold 20.3K
Granted 28.1K · Sold 15.9K
Granted 6.3K
Granted 6.3K · Bought 10.0K
Granted 6.3K
Granted 6.3K
Granted 6.3K
Granted 6.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Tempus AI, Inc.10% owner · 15 transactions | — | 13.04M | — | 3.82M | — |
| Hall Christopher MChief Executive Officer, Director · 10 transactions | +4.9% | 236.0K | 287.5K | — | 276.5K |
| Tachibana AaronCFO AND COO · 25 transactions | +5.4% | 203.8K | 274.3K | — | 268.8K |
| Chen RichardPresident and CMO · 12 transactions | +39.1% | 173.9K | 46.9K | — | 20.3K |
| Moore Stephen MichaelSVP and Chief Legal Officer · 9 transactions | +15.2% | 92.3K | 28.1K | — | 15.9K |
| Shoff LonnieDirector · 1 transaction | +20.2% | 37.2K | 6.3K | — | — |
| Myers Woodrow A JrDirector · 2 transactions | +100.8% | 32.4K | 6.3K | 10.0K | — |
| Bloom Olivia KyusukDirector · 1 transaction | +29.7% | 27.3K | 6.3K | — | — |
| Bowman A BlaineDirector · 1 transaction | +46.3% | 19.8K | 6.3K | — | — |
| Eastham KarinDirector · 1 transaction | +46.3% | 19.8K | 6.3K | — | — |
| Widder Kenneth JDirector · 1 transaction | — | 6.3K | 6.3K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 3 years: +3.25M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.